Herpes Simplex Virus (e.g., Hsv-1, Hsv-2, Etc.) Patents (Class 424/231.1)
  • Patent number: 11453915
    Abstract: Provided in the present invention is the use of the miR-338 cluster as a marker of postmenopausal osteoporosis. In the present invention, it was found that the miR-338 cluster such as miR-338-3p and/or miR-3065-5p are highly expressed in patients with postmenopausal osteoporosis, and it can be used as a marker of postmenopausal osteoporosis, used for preparing an auxiliary diagnostic kit for postmenopausal osteoporosis, which can specifically detect the expression level of the miR-338 cluster in tissues, and is used for non-invasive and early auxiliary diagnosis of postmenopausal osteoporosis in clinic. In addition, inhibitors of the miR-338 cluster have the efficacy of promoting osteogenesis and can be used for treating or preventing postmenopausal osteoporosis.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: September 27, 2022
    Assignee: Wuhan University
    Inventors: Huan Liu, Chujiao Lin, Zhi Chen
  • Patent number: 11390650
    Abstract: The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: July 19, 2022
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Feng Yao
  • Patent number: 11185564
    Abstract: The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: November 30, 2021
    Assignee: Krystal Biotech, Inc.
    Inventors: Suma Krishnan, Pooja Agarwal
  • Patent number: 10612005
    Abstract: The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: April 7, 2020
    Assignee: REPLIMUNE LIMITED
    Inventor: Robert Coffin
  • Patent number: 10076568
    Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 18, 2018
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: William Jacobs, Jr., Pablo A. Gonzalez Munoz, Betsy Herold, Christopher Petro
  • Patent number: 9328144
    Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: May 3, 2016
    Assignees: UNIVERSITY OF WASHINGTON, Erasmus University Medical Center Rotterdam (Erasmus MC)
    Inventors: David M. Koelle, George M. G. M. Verjans
  • Patent number: 9205146
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: December 8, 2015
    Assignees: Vical Incorporated, THE UNIVERSITY OF WASHINGTON
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 9044447
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: April 3, 2010
    Date of Patent: June 2, 2015
    Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHISON CANCER RESEARCH CENTER
    Inventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
  • Publication number: 20150147355
    Abstract: The present invention relates to a vaccination strategy that establishes protective immunity, including a protective memory T-cell population.
    Type: Application
    Filed: March 8, 2013
    Publication date: May 28, 2015
    Inventors: Akiko Iwasaki, Norifuma Iijima, Haina Shin
  • Publication number: 20150071965
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: October 27, 2014
    Publication date: March 12, 2015
    Inventors: Paul JOHNSON, Robert L. MARTUZA, Samuel D. RABKIN, Tomoki TODO
  • Publication number: 20150056181
    Abstract: Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.
    Type: Application
    Filed: August 8, 2014
    Publication date: February 26, 2015
    Inventors: Adah Almutairi, Nadezda Fomina, Jagadis Sankaranarayanan
  • Patent number: 8962262
    Abstract: Methods for producing a protein extract from cells, such as cells containing viral proteins, are provided. In general terms, the methods involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent, neutralizing the pH of the intermediate composition to produce the protein extract. Kits and compositions for practicing the subject methods are also provided.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: February 24, 2015
    Assignees: Arbor Vita Corporation, Becton, Dickinson and Company
    Inventors: Stephen Lovell, Lydia Blank, Virginia Crews, Nancy Hasse, Peter Lu, Johannes Schweizer, John Mantlo
  • Publication number: 20150037367
    Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
    Type: Application
    Filed: June 29, 2012
    Publication date: February 5, 2015
    Inventors: David Huw Davies, Xiaowu Liang, Philip Felgner
  • Publication number: 20150037355
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: January 4, 2012
    Publication date: February 5, 2015
    Applicants: SILLAJEN, INC., JENNEREX INC.
    Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • Patent number: 8945531
    Abstract: A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: February 3, 2015
    Assignee: The University of Tokyo
    Inventors: Tomoki Todo, Hiroshi Fukuhara
  • Publication number: 20150030631
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Applicants: VICAL INCORPORATED, The University of Washington
    Inventors: ADRIAN VILALTA, MICHAL MARGALITH, LICHUN DONG, DAVID M. KOELLE
  • Publication number: 20150010597
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2, VP11/12, and VP13/14 polypeptides.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 8, 2015
    Applicants: Vical Incorporated, The University Of Washington
    Inventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
  • Publication number: 20150010596
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 8, 2015
    Applicants: Vical Incorporated, The University of Washington
    Inventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8927251
    Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: January 6, 2015
    Assignee: The University of Chicago
    Inventors: Guoying Zhou, Bernard Roizman
  • Publication number: 20150004195
    Abstract: The present disclosure provides a method to prepare purified enveloped viral particle preparations employing ion ex change chromatography and tangential flow filtration.
    Type: Application
    Filed: January 9, 2013
    Publication date: January 1, 2015
    Inventors: Sophia Mundle, Stephen Anderson, Simon Delagrave
  • Publication number: 20140370055
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 18, 2014
    Applicants: Vical Incorporated, THE UNIVERSITY OF WASHINGTON
    Inventors: Adrian VILALTA, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8911747
    Abstract: This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: December 16, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Harvey M. Friedman, Elizabeth E. Brittle, Fushan Wang
  • Publication number: 20140363469
    Abstract: The present invention is directed to the generation of attenuated viruses or viral transcripts for the production of vaccines by incorporating microRNA binding sites within the viral target sequence of the pathogen.
    Type: Application
    Filed: January 16, 2013
    Publication date: December 11, 2014
    Inventors: Rachel Meyers, Brian Bettencourt, Jamie Evan Wong, John M. Maraganore
  • Patent number: 8877211
    Abstract: A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 UL49.5?30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 UL49.5?30-32 CT-null/gE CT?/Us9? virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: November 4, 2014
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Shafiqul I. Chowdhury, Hui Yong Wei
  • Patent number: 8871193
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: October 28, 2014
    Assignees: Catherex, Inc., The General Hospital Corporation, Georgetown University
    Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Patent number: 8871223
    Abstract: This invention provides methods of vaccinating a subject against a Herpes Simplex Virus (HSV) infection and disorders and symptoms associated with same, and impeding, inhibiting, reducing the incidence of, and suppressing HSV infection, neuronal viral spread, formation of zosteriform lesions, herpetic ocular disease, herpes-mediated encephalitis, and genital ulcer disease in a subject, comprising the step of contacting the subject with a mutant strain of the HSV, containing an inactivating mutation in a gene encoding a gE, gI, Us9, or other proteins.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: October 28, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Harvey Friedman, Elizabeth E. Zumbrun, Fushan Wang
  • Publication number: 20140314811
    Abstract: The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Feng YAO
  • Patent number: 8865185
    Abstract: This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same and inducing an anti-HSV immune response in a subject comprising the step of contacting the subject with a composition comprising a mutant HSV strain comprising an inactivating mutation in a Us8 gene, followed by a second contacting with the composition.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: October 21, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Harvey Friedman, Elizabeth E. Zumbrun
  • Patent number: 8852611
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: October 7, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Maragalith, Lichun Dong, David M. Koelle
  • Patent number: 8852610
    Abstract: This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: October 7, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Maragalith, Lichun Dong, David M. Koelle
  • Patent number: 8852602
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: October 7, 2014
    Inventors: David M. Koelle, Lawrence Corey
  • Patent number: 8840903
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2, VP11/12, and VP13/14 polypeptides.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: September 23, 2014
    Assignee: Vical Incorporated
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8840904
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV VP11/12 polypeptides.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 23, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8834894
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV gD2 polypeptides.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 16, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8828408
    Abstract: This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (HSV), such as HSV VP13/14 polypeptides.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 9, 2014
    Assignees: Vical Incorporated, The University of Washington
    Inventors: Adrian Vilalta, Michal Margalith, Lichun Dong, David M. Koelle
  • Patent number: 8809047
    Abstract: The present invention is directed to Herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: August 19, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Feng Yao
  • Patent number: 8802109
    Abstract: A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: August 12, 2014
    Assignees: University of Kansas, Southern Illinois University
    Inventors: David Davido, William Halford
  • Patent number: 8790659
    Abstract: Disclosed are a recombinant DNA molecule encoding a fusion protein comprising a SlpA chaperone and a target polypeptide wherein human FK506 binding proteins (FKBPs) are excluded as target polypeptides, a corresponding expression vector encoding said fusion protein as well as host cells transformed with said expression vector. Also disclosed are a method for producing the fusion protein, a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide. A further aspect of the invention is the use of the recombinantly produced fusion protein, and a reagent kit containing a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: July 29, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Christian Scholz, Elke Faatz, Urban Schmitt, Peter Schaarschmidt
  • Publication number: 20140193460
    Abstract: Provided herein are, inter alia, vaccines and methods of using the same for the treatment or prevention of Herpesvirus infections.
    Type: Application
    Filed: December 26, 2013
    Publication date: July 10, 2014
    Applicant: The Regents of the University of California
    Inventors: Deborah H. Spector, Christopher S. Morello, Kimberly A. Kraynyak
  • Patent number: 8765444
    Abstract: Provided herein are methods and compositions for use in treating HSV-related conditions and diseases.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: July 1, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Bin He, Dustin Verpooten, Yijie Ma
  • Patent number: 8747856
    Abstract: The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition comprising a fully human binding fragment of an antibody for ocular topical administration for treatment or diagnosis of an ocular disease. In particular, the antibody neutralizes HSV1 and HSV2.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: June 10, 2014
    Assignee: Ribovax Biotechnologies S.A.
    Inventors: Claire Abadie, Jean-Marc Combette, Catherine Deloche, Robert Anthony Williamson
  • Publication number: 20140093537
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of administering the same (e.g., via a heterologous prime/boost protocol (e.g., utilizing the same nanoemulsion in each the prime and boost administrations)) to induce immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Application
    Filed: September 30, 2013
    Publication date: April 3, 2014
    Applicants: NANOBIO CORPORATION, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James R. Baker, JR., Douglas Smith, Ali I. Fattom, Jakub Simon
  • Patent number: 8680068
    Abstract: The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 25, 2014
    Assignee: BioVex Limited
    Inventor: Robert S. Coffin
  • Publication number: 20140004081
    Abstract: The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
    Type: Application
    Filed: March 15, 2012
    Publication date: January 2, 2014
    Applicant: THE UNIVERSITY OF BIRMINGHAM
    Inventors: Mark Cobbold, David Millar
  • Patent number: 8617564
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: December 31, 2013
    Assignee: Genocea Biosciences, Inc.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne, George R. Siber
  • Publication number: 20130309262
    Abstract: The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: May 10, 2013
    Publication date: November 21, 2013
    Applicant: University of Washington
    Inventor: University of Washington
  • Publication number: 20130280299
    Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 24, 2013
    Inventors: Paul JOHNSON, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
  • Publication number: 20130273107
    Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: ADRIAN VILALTA, MICHAL MARGALITH, LICHUN DONG, DAVID M. KOELLE
  • Publication number: 20130273101
    Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 17, 2011
    Publication date: October 17, 2013
    Applicant: EYEGENE, INC.
    Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won Il Yoo
  • Publication number: 20130273108
    Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 17, 2013
    Inventors: ADRIAN VILALTA, MICHAL MARGALITH, LICHUN DONG, DAVID M. KOELLE